MedTrace Logo

Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)

NCT00092131 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2022-02-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of an approved medication being studied in support of a new approach in the prevention of exercise-induced asthma (a worsening of asthma caused by exercise, also known as exercise-induced bronchospasm), in participants who have a history of worsening asthma after exercise.

Conditions

  • Asthma, Exercise-Induced

Interventions

DRUG

Comparator: Montelukast

Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge

DRUG

Comparator: Placebo

Placebo tablet administered orally as a single witnessed dose before exercise challenge

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
15 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2003-11-30
Completion
2003-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00092131 on ClinicalTrials.gov